Atherosclerotic Cardiovascular Disease

Trials show most heart supplements don’t lower LDL or prevent events; learn why omega‑3s, vitamins and red yeast rice fall short of statins.

New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.

New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.

New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.

New guidance shows how risk enhancers and coronary calcium scores refine statin decisions, including handling incidental CAC on routine CT scans.

New ACC/AHA lipid update explains PREVENT risk equations, updated thresholds, and when to start statins or CAC scoring to prevent heart attacks.

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

This conference preview with Kathryn Berlacher, MD, MS, and Kristen Campbell, PharmD, highlights the top 6 trials to watch at ACC 2026.

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Catch up with major FDA decisions, critical conference news, and more.

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.

Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

Data from 4 of the most impactful trials presented at the American Heart Association Scientific Sessions 2025.

Navar discusses the groundbreaking results of this phase 3 trial, as well as the implications of an oral PCSK9 inhibitor for treatment adherence and persistence.

This first-in-human phase 1 trial resulted in a groundbreaking reduction in both LDL cholesterol and triglycerides for the first time in history.

Adding evolocumab to existing lipid-lowering therapies significantly reduced first MACE risk, highlighting its efficacy in reducing cardiovascular mortality.